111 Capital’s Quest Diagnostics DGX Stock Holding History

111 Capital’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,343	Closed	-$407K	–	363
2025 Q4	$407K	Buy	+2,343	New	+$427K	0.09%	182

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

111 Capital's DGX Position: Q1 2026 in Review

111 Capital sold out of Quest Diagnostics (DGX) in Q1 2026, closing a stake of 2,343 shares — an estimated $407K sold.

111 Capital first reported a position in DGX in Q4 2025 and held it in 1 quarter. The position peaked at $407K in Q4 2025. 1,067 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

111 Capital reported no remaining Quest Diagnostics position as of Q1 2026 after selling out during the quarter.
111 Capital sold 2,343 Quest Diagnostics shares in Q1 2026, an estimated $407K.
111 Capital first reported a position in Quest Diagnostics in Q4 2025 and held it in 1 quarter.
111 Capital's Quest Diagnostics position peaked at $407K in Q4 2025.
1,067 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on 111 Capital's 13F filing for Q1 2026, filed 11 May 2026.